Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Capital Expenditures (2016 - 2022)

Historic Capital Expenditures for RedHill Biopharma (RDHL) over the last 11 years, with Q3 2022 value amounting to -$22000.0.

  • RedHill Biopharma's Capital Expenditures fell 476.19% to -$22000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was -$198000.0, marking a year-over-year decrease of 7217.39%. This contributed to the annual value of -$9000.0 for FY2024, which is 1818.18% up from last year.
  • Per RedHill Biopharma's latest filing, its Capital Expenditures stood at -$22000.0 for Q3 2022, which was down 476.19% from -$163000.0 recorded in Q2 2022.
  • Over the past 5 years, RedHill Biopharma's Capital Expenditures peaked at -$1000.0 during Q3 2019, and registered a low of -$242000.0 during Q1 2020.
  • Over the past 5 years, RedHill Biopharma's median Capital Expenditures value was -$20000.0 (recorded in 2020), while the average stood at -$51631.6.
  • As far as peak fluctuations go, RedHill Biopharma's Capital Expenditures surged by 9803.92% in 2018, and later tumbled by 1650000.0% in 2020.
  • Over the past 5 years, RedHill Biopharma's Capital Expenditures (Quarter) stood at -$5000.0 in 2018, then tumbled by 560.0% to -$33000.0 in 2019, then crashed by 48.48% to -$49000.0 in 2020, then skyrocketed by 93.88% to -$3000.0 in 2021, then crashed by 633.33% to -$22000.0 in 2022.
  • Its Capital Expenditures was -$22000.0 in Q3 2022, compared to -$163000.0 in Q2 2022 and -$13000.0 in Q1 2022.